



July 08, 2025

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Symbol: LUPIN

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") – Strategic Arrangement

Pursuant to Regulation 30 read with Schedule III of the Listing Regulations, we hereby inform that the Company has entered into a License and Supply Agreement with Zentiva, k.s., for commercialization of Lupin's biosimilar Certolizumab Pegol.

The detailed disclosures as required under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and other applicable circulars, in respect of aforesaid arrangement is enclosed herewith as Annexure I.

You are requested to kindly take the above on record.

For LUPIN LIMITED

AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)

Encl.: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com



Annexure I

Disclosure as per Regulation 30 of Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and other applicable circulars issued in this regard.

Sr. No.	Particulars	Details
1.	Name of the entity(ies) with whom agreement/JV is signed;	Zentiva, k.s. Czech Republic.
2.	Area of agreement/JV;	Agreement for commercialization of Lupin's biosimilar Certolizumab Pegol.
3.	Domestic/international;	Across multiple international markets excluding Australia, Japan, Brazil, Philippines, and India.
4.	Share exchange ratio/JV ratio;	Not applicable
5.	Scope of business operation of agreement/JV;	Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories, whereas, Zentiva will oversee commercialization activities in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.
6.	Details of consideration paid/ received in agreement/JV;	Non-refundable payment by Zentiva to the Company, based on achievement of regulatory milestone up to USD 50 million (including up-front fees of USD 10 million upon execution of the agreement). Both parties will invest in the development of the new biosimilar. The profits from the defined markets will be shared between the two companies.
7.	Significant terms and conditions of agreement/JV in brief;	Same as stated in point (5) above.
8.	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	There is no acquisition of entity proposed in the transaction. Further, the arrangement is with Zentiva which is not a related party. Hence, the transaction does not fall within the ambit of related party transaction. None of the promoter/ promoter group/ group companies have any interest in the arrangement.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com



9.	Size of the entity(ies);	The agreement has been entered with Zentiva, k.s. which is a leading company focused on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond.
10.	Rationale and benefit expected.	This collaboration with Zentiva aims to expand Lupin's market reach and provide high-quality and cost-effective biosimilar to patients worldwide.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com